By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies this week said that it had completed the acquisition of certain assets of A2 Technologies for an undisclosed sum. Agilent inked the agreement last month to acquire specific assets of A2 Technologies, a Danbury, Conn.-based developer of Fourier transform infrared technology for lab and field use.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.